Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SuperGen, Abbott deal

By WIR Staff | Jan 4, 2000 | 8:00 AM GMT

ABT will exclusively market worldwide SUPG's rubitecan (RFS 2000) oral

Read the full 100 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE